title: The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
abstract: OBJECTIVE
  In a trial to improve the diagnostic efficacy of conventional urine cytology we determine survivin RNA and matrix metalloproteinase 2 and 9 in urine of bladder cancer cases.
  
  
  METHODS
  Voided urine specimens were collected from patients with histologically confirmed bladder urothelial carcinoma (Group 1; n=46), urological patients without urothelial carcinoma (Group 2; n=20), and healthy volunteers (Group 3; n=20). Urine cytology, survivin RNA was estimated by qualitative nested RT-PCR and MMP-2, MMP-9 activity were detected by gelatin zymography. The expression of survivin RNA and matrix metalloproteinase 2 and 9 in bladder cancer was compared with benign and normal cases.
  
  
  RESULTS
  Positivity rates of survivin RNA and MMPs zymography were significantly different among the 3 groups. Urine survivin detection by qualitative nested RT-PCR showed 76.1% sensitivity and 95% specificity. The overall sensitivity, specificity of urinary MMP zymography was 67.3%, 90% respectively. The combined use of urine cytology with urine survivin or MMPs zymography increased sensitivity of urine cytology from 50% to 84.7%. The highest sensitivity (95.6%) was obtained on combining the three markers.
  
  
  CONCLUSIONS
  Survivin RNA and MMPS zymography can be considered as promising noninvasive markers for bladder cancer early detection. Combined use of the three markers improved the sensitivity for detecting bladder cancer.
authors.affiliation: Biochemistry Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. dr sanaa eissa@yahoo.com
authors.forename: Sanaa
authors.initials: S
authors.lastname: Eissa
authors.forename: Soheir
authors.initials: S
authors.lastname: Badr
authors.forename: Shadia Abd
authors.initials: SA
authors.lastname: Elhamid
authors.forename: Azza Salah
authors.initials: AS
authors.lastname: Helmy
authors.forename: Mohamed
authors.initials: M
authors.lastname: Nour
authors.forename: Mohamed
authors.initials: M
authors.lastname: Esmat
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D002277:Carcinoma / Q000175:diagnosis / Q000201:enzymology / Q000652:urine*; D016022:Case-Control Studies; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics* / Q000652:urine; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000652:urine*; D020780:Matrix Metalloproteinase 9 / Q000652:urine*; D008875:Middle Aged; D012333:RNA, Messenger / Q000652:urine*; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D000077022:Survivin; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000652:urine*
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D012333:RNA, Messenger; D000077022:Survivin; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9